Mitchell, P.L., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., et al. (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6, 146-151. doi:10.3816/CCC.2006.n.032

has been cited by the following article:

• TITLE: Oxaliplatin induced hyperexcitability syndrome in patient with appendiceal adenocarcinoma

  AUTHORS: Nicola Jabbour, Maher Alchreiki, Mohammad Hussain

  KEYWORDS: Oxaliplatin; Peripheral Neuropathy; Neuromyotonia; Hyperexcitability Syndrome; Appendiceal Adenocarcinoma; Sodium Channels

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.4, July 8, 2013

  ABSTRACT: Oxaliplatin is a novel platinum compound with clinical activity against several solid tumors. It has been associated with sensory neuropathies and, rarely, a neuromyotonia-like hyperexcitability syndrome; a form of peripheral neuropathy manifested by tremor and twitching activity of muscles. We present a case of hyperexcitability syndrome developed during the treatment of stage III appendiceal adenocarcinoma with oxaliplatin-containing regimen and was successfully treated with Pregabalin.